| Daniel James Sengenberger, DO | |
|
850 Siskiyou Blvd Ste 7, Ashland, OR 97520-2125 | |
| (541) 482-2920 | |
| Not Available |
| Full Name | Daniel James Sengenberger |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 19 Years |
| Location | 850 Siskiyou Blvd Ste 7, Ashland, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265402440 | NPI | - | NPPES |
| Entity Name | Daniel J Sengenberger |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891441903 PECOS PAC ID: 7012304926 Enrollment ID: O20220425000091 |
News Archive
Researchers from the University at Buffalo, School of Dental Medicine did a follow-up evaluation on 106 postmenopausal women and found that during an average of 11.7 years follow-up, 57.5 percent of the participants lost at least one tooth.
Researchers have identified the mechanism used by the deadly MERS virus to transmit from bats to humans. Bats are a native reservoir for MERS and the finding could be critical for understanding the animal origins of the virus, as well as preventing and controlling the spread of MERS and related viruses in humans.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 31, 2011 for the review of the Contrave® (naltrexone sustained release (SR)/bupropion SR) New Drug Application (NDA).
Bioengineers at the University of California San Diego have developed a control system that could make CAR T-cell therapy safer and more powerful when treating cancer.
OSI Systems, Inc., a vertically-integrated provider of specialized electronic products for critical applications in the Security and Healthcare industries, today announced that its Healthcare division, Spacelabs Healthcare, has received a contract from Thomas Memorial Hospital in Charleston, West Virginia for a broad range of patient monitoring products.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel James Sengenberger, DO 1316 E Main St, Medford, OR 97504-7561 Ph: (541) 622-5609 | Daniel James Sengenberger, DO 850 Siskiyou Blvd Ste 7, Ashland, OR 97520-2125 Ph: (541) 482-2920 |
News Archive
Researchers from the University at Buffalo, School of Dental Medicine did a follow-up evaluation on 106 postmenopausal women and found that during an average of 11.7 years follow-up, 57.5 percent of the participants lost at least one tooth.
Researchers have identified the mechanism used by the deadly MERS virus to transmit from bats to humans. Bats are a native reservoir for MERS and the finding could be critical for understanding the animal origins of the virus, as well as preventing and controlling the spread of MERS and related viruses in humans.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 31, 2011 for the review of the Contrave® (naltrexone sustained release (SR)/bupropion SR) New Drug Application (NDA).
Bioengineers at the University of California San Diego have developed a control system that could make CAR T-cell therapy safer and more powerful when treating cancer.
OSI Systems, Inc., a vertically-integrated provider of specialized electronic products for critical applications in the Security and Healthcare industries, today announced that its Healthcare division, Spacelabs Healthcare, has received a contract from Thomas Memorial Hospital in Charleston, West Virginia for a broad range of patient monitoring products.
› Verified 9 days ago